KCT0006651
Active, not recruiting
未知
Optimal duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms: A prospective randomized multicenter trial
ConditionsDiseases of the circulatory system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the circulatory system
- Sponsor
- Seoul National University Bundang Hospital
- Enrollment
- 528
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adults aged 19 years or older
- •2\) Those who plans to perform coil embolization under stent\-assisted unruptured cerebral aneurysm, and the number of platelets measured before the procedure corresponds to the following conditions:
- •a) aspirin reaction unit (ARU) \< 550
- •b) P2Y12 reaction unit (PRU): 85\~219
- •3\) Modified Rankin Scale (mRS) Score\= 2 at the screening
- •4\) Those who has fully understand to the explanation of this study and has finally agreed.
Exclusion Criteria
- •1\) Those who have neurological disabilities at the cerebral aneurysm procedure (mRS 3\) 3\)
- •2\) Those who are allergic to aspirin and clopidogrel.
- •3\) Those who have a high risk of excessive bleeding when taking medication, such as internal bleeding or severe stomach ulcers.
- •4\) Those with bleeding tendency or blood clotting problems
- •5\) Those who need to maintain anticoagulants or double antiplatelet treatment due to existing diseases such as cardiovascular disease (excluding patients who have maintained aspirin at mono and patients who need to maintain dual antiPLTs.)
- •6\) Those at high risk of stroke (such as Moyamoya disease, cerebrovascular abnormalities, etc. in cases of atrial fibrillation patients requiring double antiplatelets or anticoagulants, intracranial or intravascular obstruction or more than 70% stenosis).
- •7\) Those who have uncontrolled heart failure or angina.
- •8\) Those with a malignant tumor that needs treatment
- •9\) Those who are pregnant or breastfeeding.
- •10\) Those who are unconscious at the time of diagnosis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization of the superficial femoral artery.Patients with diagnosis of lower limbs PAOD, ranging from stage 2 to 5 according to Rutherford classification and lesions of the SFA treated by endovascular revascularizationMedDRA version: 20.0Level: LLTClassification code 10016430Term: Femoral artery stenosisSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-000532-94-ITFONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO78
Completed
Not Applicable
ShorT and OPtimal duration of Dual AntiPlatelet Therapy studycoronary artery diseaseJPRN-UMIN000008878Kyoto University Hospital1,500
Active, not recruiting
Phase 4
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-3 studyIschemic heart disease, stable angina, myocardial infarctionJPRN-jRCTs052200114Ono Koh6,000
Active, not recruiting
Phase 4
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-2 study for patients with ACSJPRN-jRCTs052180193Ono Koh3,000
Completed
Not Applicable
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor StentCoronary Artery DiseaseNCT00418860Samsung Medical Center1,200